Abstract: Compositions contain citrulline and leucine or a metabolite thereof, such as hydroxyisocaproic acid (HICA) or beta-hydroxy-beta-methylbutyrate (HMB), including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for treatment of pre-diabetes, metabolic syndrome, or diabetes.

Abstract: The present disclosure provides compositions and methods for providing a health benefit to an animal utilizing ferulic acid and histidine. For example, a composition can contain ferulic acid and histidine in therapeutically effective amounts for providing the health benefit to the animal.

Abstract: A method for reducing postprandial glucose from a balanced meal includes orally administering to an individual a composition containing mulberry extract together with the meal. The postprandial glucose is reduced relative to postprandial glucose from administering a corresponding composition comprising mulberry extract before subsequent administration of the balanced meal.

Abstract: The present invention relates to a digestible carbohydrate composition comprising at least 65% (w/w) glucose-based saccharides on a dry basis, wherein said saccharides have a reducing end and D-glucose monomers linked with alternating ?1-6 and ?1-3 glycosidic linkages, wherein a maltose unit is present at the reducing end; and 0.1 to 30% (w/w) of fructose equivalents on a dry basis; wherein said glucose-based saccharides have an average degree of polymerization greater than 12.

Abstract: Compositions contain citrulline and leucine or a metabolite thereof, such as hydroxyisocaproic acid (HICA) or beta-hydroxy-beta-methylbutyrate (HMB), including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for treatment of pre-diabetes, metabolic syndrome, or diabetes.

Abstract: Compositions contain citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of pre-diabetes, metabolic syndrome, hyperglycemia, or diabetes.

Abstract: A method for reducing postprandial glucose from a meal includes orally administering to an individual a composition containing whey protein micelles (WPM) and then subsequently orally administering the meal to the individual after the oral administration of the composition containing the WPM and within about one hour of the oral administration of the composition containing the WPM. For example, the meal can be administered about thirty minutes after the administration of the composition containing the WPM. The postprandial glucose is reduced relative to postprandial glucose from administering a corresponding composition comprising whey protein isolate.

Abstract: Use of a compound having the formula (1), (2), (3), or (4) or combinations thereof, for providing a source of butyrate with improved organoleptic properties wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons the prevention and/or treatment of metabolic disorders.

Abstract: 1.

Abstract: The present disclosure provides compositions and methods for providing a health benefit to an animal utilizing ferulic acid and histidine. For example, a composition can contain ferulic acid and histidine in therapeutically effective amounts for providing the health benefit to the animal.

Abstract: Compositions contain citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of pre-diabetes, metabolic syndrome, hyperglycemia, or diabetes.

Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.

Abstract: The present disclosure relates generally to compositions that comprise citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of metabolic syndrome, hyperglycemia, and/or hyperinsulinemia.

Abstract: The present disclosure relates generally to compositions that comprise citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of metabolic syndrome, hyperglycemia, and/or hyperinsulinemia.

Abstract: The present invention relates to predicting the risk of developing hypertriglyceridemia in a subject by quantitating the amount of enterobacteria, e.g., E. coli, in the subject's gastrointestinal system. The invention also relates to treating a subject with hypertriglyceridemia or at risk of having the condition.

Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.

Abstract: The present invention generally relates to health benefits of natural compounds. In particular, the present invention relates peltatins, a group of natural compounds that can be used to treat, prevent or alleviate chronic inflammatory disorders. For example, the present invention concerns a composition comprising at least one peltatin for use in the treatment or prevention of chronic inflammatory disorders.

Abstract: The present invention relates to the field of metabolic disorders and aims to identify natural compounds that can be used effectively in this field. In particular, the present invention provides a composition comprising at least one peltatin for use in the treatment or prevention of metabolic disorders or risk factors thereof.

Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.

Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus helveticus CNCM I-4095 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.